CNS Pharmaceuticals, Inc. (CNSP)
CNSP Stock Price Chart
Explore CNS Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze CNSP price movements and trends.
CNSP Company Profile
Discover essential business fundamentals and corporate details for CNS Pharmaceuticals, Inc. (CNSP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Nov 2019
Employees
4.00
Website
https://www.cnspharma.comCEO
John Michael Climaco
Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
CNSP Financial Timeline
Browse a chronological timeline of CNS Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 13 Nov 2025
Earnings released on 14 Aug 2025
EPS came in at -$6.42 surpassing the estimated -$9.60 by +33.13%.
Stock split effective on 22 Jul 2025
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 21 Feb 2025
Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2024
EPS came in at -$150.06 falling short of the estimated -$0.10 by -149.96K%.
Earnings released on 14 Aug 2024
EPS came in at -$4.03K falling short of the estimated -$3.59K by -12.50%.
Stock split effective on 5 Jun 2024
Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 May 2024
EPS came in at -$12.30K .
Earnings released on 1 Apr 2024
EPS came in at -$28.51K surpassing the estimated -$57.00K by +49.98%, while revenue for the quarter reached $6.36K .
Earnings released on 14 Nov 2023
EPS came in at -$32.41K surpassing the estimated -$51.90K by +37.55%.
Earnings released on 14 Aug 2023
EPS came in at -$31.21K surpassing the estimated -$84.60K by +63.11%.
Earnings released on 15 May 2023
EPS came in at -$77.73K .
Earnings released on 31 Mar 2023
EPS came in at -$2.23 surpassing the estimated -$6.00K by +99.96%.
Stock split effective on 29 Nov 2022
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Nov 2022
EPS came in at -$8.10K falling short of the estimated -$2.40 by -337.57K%.
Earnings released on 12 Aug 2022
EPS came in at -$8.10K falling short of the estimated -$2.40 by -337.57K%.
Earnings released on 16 May 2022
EPS came in at -$6.30K falling short of the estimated -$2.40 by -262.53K%.
Earnings released on 3 Mar 2022
EPS came in at -$9.00K surpassing the estimated -$18.91K by +52.38%.
Earnings released on 12 Nov 2021
EPS came in at -$12.61K surpassing the estimated -$18.91K by +33.33%.
Earnings released on 13 Aug 2021
EPS came in at -$13.51K surpassing the estimated -$14.41K by +6.25%.
Earnings released on 14 May 2021
EPS came in at -$13.51K falling short of the estimated -$3.60 by -375.09K%.
Earnings released on 12 Feb 2021
EPS came in at -$16.21K falling short of the estimated -$8.10K by -100.00%.
Earnings released on 12 Nov 2020
EPS came in at -$10.81K falling short of the estimated -$3.60 by -300.05K%.
CNSP Stock Performance
Access detailed CNSP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.